Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Posted on 17 dicembre 2014
Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G.
J Cancer Res Clin Oncol. 2008 Jan;134(1):51-7. Epub 2007 Jun 26.